^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QN-023a

    i
    Other names: QN-023a
    Associations

    News

    Trials
    Company:
    Qihan Biotech
    Drug class:
    NK cell stimulant, CD33 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=19, Recruiting, Zhejiang University
    New P1 trial
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    cytarabine • fludarabine IV • QN-023a
    over1year
    Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia (ASH 2022)
    Immune cell therapy has become a cornerstone in cancer therapy. When administered in combination with daratumumab, QN-023a demonstrated superior ADCC compared to unmodified iPSC-derived NK cells against primary AML blasts from patients. Together, we have engineered iPSC-derived QN-023a NK cells as promising clinical drug candidates for treatment of AML.
    IO biomarker
    |
    CD33 (CD33 Molecule) • IL15 (Interleukin 15) • NKG2D (killer cell lectin like receptor K1)
    |
    Darzalex (daratumumab) • CD33 CAR-T • QN-023a
    over1year
    Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Institute of Hematology & Blood Diseases Hospital
    New P1 trial
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    cytarabine • fludarabine IV • QN-023a